성심산학협력단

- 가톨릭대학교 약학대학 교수 (약제학) 재직 (2010-현재)
- STH Pharm 대표
- SK 케미칼 생명과학연구소 신약연구실장 (상무이사)
- 건일제약㈜ 제약 R&D 본부장 (전무이사)
- 미국 Teva사 수석연구원 겸 Drug Product Development 그룹장
- Astellas 미국 Pharmaceutical Development 선임연구원 겸 팀장
- 글로벌 신물질 신약개발 6건 제제 및 제품화 주도 참여
- 개량신약 및 전문의약품 62건 제품화 주도, 제약기술 33건 개발 책임
- Corresponding and Co-authors in 230 Scientific Papers, Book Chapters and Patents
- 미국 Rho Chi Pharmaceutical Honor Society 회원
- 한국약제학회장, 한국에프디시법제학회 부회장, 한국신약개발연구조합 자문교수 역임/재임
- 국가과학기술심의위원회 위원, 기획재정부 국고보조사업 평가위원, 미래창조과학부 바이오의료기술개발 위원, 산업통상자원부 글로벌개량신약개발사업 운영위원장, 식품의약품안전처 식품의약품안전기술위원회, 의약품신속심사자문단, 의약품심사자문단, 초기임상 시험심사자문단, 중앙약사심의위원, DUR위원 역임/재임	

Euichaul Oh, Ph.D., is currently a Professor of Pharmaceutics in the College of Pharmacy at the Catholic University of Korea since 2010. Prof. Oh received his B.S. in Pharmacy and M.S. in Physical Pharmacy from Seoul National University and his Ph.D. in Pharmaceutics from the University of Iowa. After joining the U.S. pharmaceutical industry in 1999, he worked as a Team Leader Scientist for Astellas and then worked as a Group Leader Scientist for Teva being involved in many R&D projects for pharmaceutical development of new drug entities and drug delivery technologies. After moving to Korean pharmaceutical industry in 2006, Dr. Oh was leading pharmaceutical R&D as Senior Vice President at Kuhnil Pharm, heading new drug development as CSO at SK Chemicals, and responsible for overall functions of drug development as CEO at STH Pharm. He was actively involved in the commercialization of six global new drug development, and was responsible for the product development of 62 new prescription drugs and the development of 33 pharmaceutical technologies. He has authored and co-authored more than 230 peer-reviewed scientific papers, book chapters and patents in pharmaceutical and DDS development. Prof. Oh served as President for the Korean Society of Pharmaceutical Sciences and Technology as well as is currently a member of the Rho Chi Pharmaceutical Honor Society in the USA.